Background: The emergence of carbapenemases in Enterobacteriaceae is driving a search for therapeutic alternatives. We tested ACHN-490, a sisomicin derivative that evades all plasmid-mediated aminoglycosidemodifying enzymes, against 82 carbapenem-resistant Enterobacteriaceae isolates. Comparators included internationally and locally available aminoglycosides.
Introduction
Carbapenemases have been slow to emerge in the Enterobacteriaceae, but are now increasingly prevalent. They are notable for their diversity, including enzymes belonging to molecular classes A (KPC, SME and IMI types), B (IMP, NDM and VIM) and D (OXA-48). 1, 2 Several of these mechanisms have strong regional links. Klebsiella pneumoniae with KPC carbapenemases have spread extensively in the USA, Israel and Greece, with much of the problem due to a single producer clone belonging to sequence type (ST) 258. 1, 3 Simultaneously, K. pneumoniae with VIM metallocarbapenemases have accumulated in Greece, though with plasmid spread as the major driver, not clonal dissemination, 4 whilst another metallo-carbapenemase, NDM-1, has become widely scattered among Enterobacteriaceae in India and Pakistan, with repeated import to the UK and elsewhere via patient transfers. 5 IMP metallo-carbapenemases are widely recorded, too, but lack clear geographical associations. Lastly, K. pneumoniae with OXA-48 carbapenemase are widespread in Turkey, and reported also in the UK, Middle East, North Africa, India and Argentina. 6 Many carbapenemase-producing Enterobacteriaceae are highly multiresistant, but may remain susceptible to one or more aminoglycoside as well as to tigecycline and/or colistin.
We sought to define more fully the activity of aminoglycosides against carbapenemase-producing Enterobacteriaceae, including not only internationally used compounds (amikacin, gentamicin and tobramycin), but also those that are available in only a few countries (arbekacin, dibekacin and isepamicin). We included apramycin, an unusual analogue used as a nonabsorbed oral agent to treat diarrhoeal diseases in animals. Lastly, we included a novel sisomicin derivative, ACHN-490 (Figure 1) , 7 which has substituents that block inactivation by all known aminoglycoside-modifying enzymes, except AAC(2 ′ )-Ia, -Ib and -Ic, which occur only as chromosomal types in Providencia spp.
Materials and methods

Bacteria
The organisms (Table 1) were clinical isolates that had mostly been collected from patients in the UK between 2006 and 2009. The strain collections were selected to represent the major carbapenem-resistant organisms in circulation, but were not consecutive and we did not seek to match the proportions of isolates against current prevalence (which is, itself, in a state of rapid change). Many source patients had a history of recent foreign travel and hospitalization. In particular, many isolates with VIM carbapenemases, and some with KPC enzymes, were epidemiologically linked to Greece, and many of those with NDM-1 enzymes were linked to India and Pakistan. Carbapenemase genes were identified previously by PCR and, in some cases, by sequencing. Strains that owed their carbapenem resistance to combinations of AmpC or extendedspectrum b-lactamase (ESBL) activity along with porin loss were characterized as described previously. 8 All seven K. pneumoniae isolates with KPC carbapenemases had been assigned to ST258, based on XbaI-PFGE profiles with ≥85% similarity to a known member of this clone. Six of the 19 isolates with OXA-48 carbapenemase belonged to a single PFGE-defined clone, prevalent at a UK renal unit. All the isolates with NDM carbapenemase were diverse by PFGE, as were all those with combinations of AmpC or ESBL and impermeability.
Most of the organisms were strikingly resistant to b-lactams. A few, particularly among those with combinations of ESBL and impermeability, remained susceptible to imipenem but not to ertapenem at European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (data not shown). Although IMP, NDM and VIM metallo-b-lactamases cannot hydrolyse aztreonam, many producers were resistant, owing to the co-production of AmpC or CTX-M enzymes. 
Results and discussion
ACHN-490
ACHN-490 had MICs of ≤0.12-2 mg/L, and mostly 0.12-0.5 mg/Las low as for the Escherichia coli ATCC 25922 control-for all the series of isolates, except that MICs for 16/17 isolates with NDM carbapenemase were ≥64 mg/L ( Table 2 ). The resistant organisms with NDM carbapenemases belonged to multiple species and, as detailed below, had high-level resistance to all the other human-use aminoglycosides, though not to apramycin. Fifteen of these 16 were examined and found to have genes encoding 16S rRNA methylases: 8 had armA and 7 had rmtC. The single remaining isolate with NDM carbapenemase was a Citrobacter freundii that was susceptible to ACHN-490 at 0.25 mg/L. It had lower-level resistance to other aminoglycosides, though with MICs above breakpoints, and lacked both armA and rmt genes.
Internationally available aminoglycosides: amikacin, gentamicin and tobramycin
Among the 65 isolates with mechanisms other than NDM carbapenemase, 39 (60%) were susceptible to gentamicin at the EUCAST breakpoint of ≤2 mg/L and another 4 (6%) were intermediate, with MICs of 4 mg/L. Corresponding numbers for tobramycin were 25 (38%) and 1 (1.5%), respectively. For amikacin, 49 (75%) were susceptible, with MICs of ≤8 mg/L, and 3 (4.6%) were intermediate, with MICs of 16 mg/L. In contrast, all 17 isolates with NDM carbapenemase were resistant to these three 'standard' aminoglycosides, 16 of them with MICs of ≥64 mg/L for tobramycin, and ≥256 mg/L for amikacin and gentamicin.
The seven K. pneumoniae isolates belonging to the ST258 international clone were resistant to tobramycin (MICs ≥32 mg/L) and intermediate or (mostly) resistant to amikacin (MICs ≥16 mg/L), whereas all except one were susceptible or intermediate to gentamicin (MICs 0.5 -4 mg/L), implying production of a 6 ′ -N-acetyltransferase. The other five isolates with 
Aminoglycosides available in only a few countries
Isepamicin is available in only a few countries, e.g. Belgium, Korea and China, and is notable for its stability to some AAC(6 ′ ) variants. It has no EUCAST breakpoints, but, based on the value of 8 mg/L proposed by Barry et al., 10 it remained active against 63/65 isolates that had carbapenem-resistance mechanisms other than NDM-1 enzyme, including many that were resistant to some or all of amikacin, gentamicin and tobramycin. Most isepamicin MICs were 1 mg/L, as recorded also for the E. coli ATCC 25922 control. All 12 isolates with KPC carbapenemases were susceptible at 8 mg/L, as were all those with IMP and OXA-48 enzymes. However, all the 17 isolates with NDM carbapenemase were resistant, 16 of them with MICs ≥256 mg/L. Putative resistance, with MICs of 16 mg/L, was also seen in two of the five isolates with VIM carbapenemases.
Arbekacin and dibekacin, both available in, e.g. Japan, showed no advantage over the internationally available analogues, with dibekacin being the least active compound tested.
Apramycin
The most surprising results were for apramycin, a non-absorbed veterinary analogue used for the oral treatment of colibacilliosis, salmonellosis and enteritis in poultry and livestock. This agent had MICs of 2-8 mg/L for the E. coli control (8 mg/L) and for virtually all the carbapenemase producers, including those with NDM-1 carbapenemase. The two exceptions were: (i) a K. pneumoniae strain with OXA-48 carbapenemase and an apramycin MIC of 32 mg/L; and (ii) a porin-deficient K. pneumoniae strain with TEM-1, SHV-11 and CTX-M-15 enzymes, and an apramycin MIC ≥256 mg/L. The former had slightly raised MICs (2 -8 mg/L) for all other aminoglycosides, including ACHN-490 (MIC 2 mg/L), but lacked substantial resistance to any analogue; it was not investigated further, though an uptake-based mechanism best explains this phenotype. The second was resistant to gentamicin, tobramycin and dibekacin (MICs ≥32 mg/L), but was susceptible to ACHN-490 (MIC 0.25 mg/L), isepamicin (MIC 1 mg/L), arbekacin (MIC 8 mg/L) and amikacin (MIC 8 mg/L). PCR showed it to carry the gene for AAC(3)-IV, an acetyltransferase that inactivates apramycin, gentamicin and tobramycin, though not amikacin or isepamicin. 11, 12 Taken together, the data indicate that, except for bacteria with NDM-1 enzyme-which was generally accompanied by ArmA or RmtC-the great majority of carbapenem-resistant Enterobacteriaceae were susceptible to one or more aminoglycoside. Among analogues currently available, isepamicin was the most widely active, but ACHN-490 was 4-fold more potent on a gravimetric basis-a potentially worthwhile advantage in this drug class. 7 ACHN-490 also remained active at ,1 mg/L against both of the two VIM + K. pneumoniae isolates that were resistant to isepamicin.
Resistance mediated by 16S rRNA methylases, to which all non-veterinary aminoglycosides tested were vulnerable, is of concern. These modify bacterial ribosomes to prevent the binding of 4,6-linked aminoglycosides. Their distribution is poorly defined, with little molecular resistance epidemiology for recent survey collections. However, they seem most prevalent in the Far East, having been found in 6.3% of Enterobacteriaceae from one hospital in China, 13 where both plasmid and clonal spread were implicated in their dissemination, 14 and in 2.8% of Enterobacteriaceae from a hospital in Korea. 15 SENTRY data for 2007-08 indicated prevalence rates among Enterobacteriaceae of 10.5% in India, 6.9% in China, 6.1% in Korea, 5% in Taiwan and 3.1% in Hong Kong, with a strong link to NDM carbapenemases in India. 16 They are most prevalent in otherwise multiresistant isolates and were found in 80/235 ESBL-producing Enterobacteriaceae from Taiwan, 17 with one isolate having both rmtB and armA genes. Although associated here and in SENTRY with NDM-1 enzyme, armA has also been found on plasmids encoding KPC carbapenemases in China. 18 In Europe, armA was found in ESBL-producing Enterobacteriaceae in Belgium 19 and Bulgaria, 20 and in a strain of Acinetobacter baumannii that spread to at least 58 UK hospitals. In the USA, it has been found only in A. baumannii 21 and in two non-typhoidal salmonellas, at least one of them epidemiologically linked to India. 22 It is striking that apramycin completely evaded ArmA-and RmtC-mediated resistance, and, although the apramycin binding site on the ribosome is vulnerable to the action of other rRNA methylases, these seem not yet to have escaped from streptomycetes to Enterobacteriaceae. 23 Unfortunately, apramycin itself is unsuitable for systemic use in animals let alone humans, owing to a narrow therapeutic index, but its unusual nucleus may provide the scaffold for future derivatives that overcome methylase-mediated resistance. In the meantime, ACHN-490 has potential to be a useful agent against many otherwise multiresistant carbapenemase producers, excluding those with 16S rRNA methylases.
